MX349176B - Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. - Google Patents

Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.

Info

Publication number
MX349176B
MX349176B MX2010004169A MX2010004169A MX349176B MX 349176 B MX349176 B MX 349176B MX 2010004169 A MX2010004169 A MX 2010004169A MX 2010004169 A MX2010004169 A MX 2010004169A MX 349176 B MX349176 B MX 349176B
Authority
MX
Mexico
Prior art keywords
osmolyte
vasoactive agent
drug delivery
transdermal drug
formulation
Prior art date
Application number
MX2010004169A
Other languages
English (en)
Other versions
MX2010004169A (es
Inventor
Stephen G Carter
Zhen Zhu
Kanu Patel
John J Masiz
Original Assignee
Biochemics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemics Inc filed Critical Biochemics Inc
Publication of MX2010004169A publication Critical patent/MX2010004169A/es
Publication of MX349176B publication Critical patent/MX349176B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application

Abstract

La presente invención se refiere a una formulación y un método para el suministro de sustancias bioactivas cuando son aplicadas a, o dentro de, la piel u otra región exterior de mamífero, por ejemplo un paciente, incluye un agente vasoactivo, un osmolito, y un ingrediente activo; la formulación es suficientemente higroscópica para crear una condición de hipertonicidad cuando es absorbida por la piel; cuando se aplica la formulación a la piel, se puede suministrar el agente vasoactivo a la dermis para hacer contacto con la vasculatura de un paciente.
MX2010004169A 2008-09-22 2009-09-22 Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. MX349176B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9912908P 2008-09-22 2008-09-22
PCT/US2009/057916 WO2010034019A1 (en) 2008-09-22 2009-09-22 Transdermal drug delivery using an osmolyte and vasoactive agent

Publications (2)

Publication Number Publication Date
MX2010004169A MX2010004169A (es) 2010-10-05
MX349176B true MX349176B (es) 2017-07-14

Family

ID=41449932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004169A MX349176B (es) 2008-09-22 2009-09-22 Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.

Country Status (7)

Country Link
US (3) US9566256B2 (es)
EP (1) EP2207536A1 (es)
BR (1) BRPI0914192A2 (es)
CA (1) CA2702604C (es)
CO (1) CO6361907A2 (es)
MX (1) MX349176B (es)
WO (1) WO2010034019A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702604C (en) 2008-09-22 2013-12-03 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
BRPI0921959A2 (pt) 2008-12-04 2017-05-30 Biochemics Inc métodos e composições para remoção de tatuagem
CA2796965C (en) 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Method for increasing permeability of an epithelial barrier
WO2011135532A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. Composite microneedle array including nanostructures thereon
CA2797205C (en) * 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of sirna
RU2585159C2 (ru) 2010-04-28 2016-05-27 Кимберли-Кларк Ворлдвайд, Инк. Устройство доставки лекарственного средства, применяемого при ревматоидном артрите
US8512770B2 (en) 2010-08-04 2013-08-20 Dominion Resources Unlimited, Llc Skin penetration composition
CA2850931A1 (en) 2011-10-27 2013-05-02 Kimberly-Clark Worldwide, Inc. Implantable devices for delivery of bioactive agents
AU2012328037B2 (en) 2011-10-27 2017-11-02 Sorrento Therapeutics, Inc. Transdermal delivery of high viscosity bioactive agents
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
BR112014013667A2 (pt) 2011-12-06 2017-06-13 Unilever Nv composição antienvelhecimento da pele
US9587169B2 (en) * 2012-01-12 2017-03-07 Courtney Gene Rogers Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
CA2906765A1 (en) 2013-03-15 2014-09-18 Biochemics, Inc. Topical formulations and methods for drug delivery
WO2015066699A1 (en) * 2013-11-04 2015-05-07 ROGERS, Courtney, Gene Low-toxicity, low-flammability, environmentally-safe, friction reducer fluid for hydraulic fracturing
CA3063870A1 (en) 2017-05-15 2018-11-22 Biochemics, Inc. Transdermally-delivered combination drug therapy for pain
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
IT201800003902A1 (it) * 2018-03-23 2019-09-23 Sebastiano Turrini Unguento a base di ibuprofene racemico transedermico
MX2021002833A (es) 2018-09-27 2021-05-27 Biophysics Pharma Inc Sistema de suministro de farmaco transdermico.
US20210259951A1 (en) * 2020-02-20 2021-08-26 North Atlantic Holdings LLC Transmucosal Drug Delivery System

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4758599A (en) * 1986-06-04 1988-07-19 American Cyanamid Company Clear, hydroalcoholic aftershave lotion which moisturizes, conditions, and prevents irritation
US4830856A (en) * 1987-01-27 1989-05-16 Peppers James M Chelation product
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
GB8905815D0 (en) 1989-03-14 1989-04-26 Beecham Group Plc Medicament
AU6974191A (en) 1989-12-20 1991-07-18 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US5093133A (en) 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
UA34430C2 (uk) 1991-05-13 2001-03-15 Дзе Бутс Компані Плс S(-)-2-(4-ізобутилфеніл)пропіонат натрію дигідрат, придатний для лікування запалення, болю і гіпертермії, фармацевтична композиція на його основі та спосіб одержання s(-)-2-(4-ізобутилфеніл)пропіонату натрію
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5451704A (en) 1992-12-23 1995-09-19 Mobil Oil Corporation Alpha-olefin oligomerization using supported metal halide catalysts
US5451407A (en) * 1993-06-21 1995-09-19 Alza Corporation Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug
US5460821A (en) * 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
US5645854A (en) * 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5853751A (en) * 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5527530A (en) * 1994-07-08 1996-06-18 The Procter & Gamble Company Alcoholic moisturizing after shave lotion
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6228873B1 (en) * 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2741262B1 (fr) * 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6527716B1 (en) * 1997-12-30 2003-03-04 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
AU6326198A (en) * 1997-02-13 1998-09-08 Lxr Biotechnology Inc. Organ preservation solution
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5922332A (en) * 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5895658A (en) * 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US6486206B1 (en) * 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
WO1999051157A1 (en) * 1998-04-07 1999-10-14 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
CA2374003C (en) * 1999-05-17 2008-02-12 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
FR2808191B1 (fr) * 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
AU2001290552A1 (en) * 2000-09-15 2002-03-26 Medical Merchandising, Inc. Pain reliever and method of use
US6635274B1 (en) * 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US7041657B2 (en) * 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
US20030091659A1 (en) * 2001-11-09 2003-05-15 Avon Products, Inc. Topical composition having undifferentiated plant seed cells and method for using same
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
AU2003208232B2 (en) * 2002-03-08 2008-05-22 Mcgill University In vitro maturation of immature human oocytes
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
ATE541562T1 (de) 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US6927206B2 (en) * 2003-06-06 2005-08-09 Procyte Corporation Compositions and methods for treatment of rosacea
US20080112909A1 (en) * 2003-06-24 2008-05-15 Ppg Industries Ohio, Inc. Compositions for providing color to animate objects and related methods
US7375139B2 (en) * 2003-08-18 2008-05-20 Aldred Katherine M Transdermal method and apparatus
MXPA06003573A (es) * 2003-09-30 2006-08-31 Kohi Corp Composiciones y metodos para tratar quemaduras.
ITMI20032322A1 (it) * 2003-11-27 2005-05-28 Carlo Ghisalberti Dispositivo atossico per facilitare la venipuntura.
WO2005091891A2 (en) 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
ES2429443T3 (es) * 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
US20050256204A1 (en) * 2004-05-11 2005-11-17 Bitter Patrick H Sr Topical phenyl-epinephrine Rosacea treatment
GB0413635D0 (en) 2004-06-18 2004-07-21 Smith & Nephew Ultrasonic treatment
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US20060062836A1 (en) * 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
US20060217690A1 (en) * 2005-03-22 2006-09-28 Bastin Norman J Method for treating various dermatological and muscular conditions using electromagnetic radiation
WO2006104660A1 (en) 2005-03-24 2006-10-05 Avery Dennison Corporation Occlusive wound dressing useful in tattoo removal
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
US20070166252A1 (en) * 2005-12-30 2007-07-19 Judy Hattendorf Method of treating skin requiring tattoo removal
WO2007086395A1 (ja) 2006-01-24 2007-08-02 Hamamatsu Foundation For Science And Technology Promotion 光線力学的療法用キット
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
WO2007143002A2 (en) * 2006-05-31 2007-12-13 Interhealth Nutraceuticals, Inc. Nutraceutical treatments for diabetic and non-diabetic wound healing
GB2458228B (en) 2006-10-12 2011-02-23 Rohto Pharma External preparation for skin
KR101069502B1 (ko) 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
WO2008109124A1 (en) 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
CA2680823A1 (en) * 2007-03-19 2008-09-25 Sirtris Pharmaceuticals, Inc. Biomarkers of sirtuin activity and methods of use thereof
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US20090123570A1 (en) * 2007-11-09 2009-05-14 Warner W Randolph Composition and method for treating sore throat
WO2009094473A1 (en) * 2008-01-22 2009-07-30 Biochemics, Inc. Methods and compositions for topical treatment of medical conditions including wounds and inflammation
CA2720816A1 (en) 2008-03-07 2009-09-11 Frank Pellegrini Ultra bright led induced tattoo removal
EP2307001A1 (en) * 2008-06-11 2011-04-13 BioChemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2726726A1 (en) 2008-09-10 2010-03-18 Thrubit B.V. Ibuprofen for topical administration
CA2702604C (en) * 2008-09-22 2013-12-03 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
BRPI0921959A2 (pt) * 2008-12-04 2017-05-30 Biochemics Inc métodos e composições para remoção de tatuagem

Also Published As

Publication number Publication date
US10537536B2 (en) 2020-01-21
US20100076035A1 (en) 2010-03-25
CA2702604A1 (en) 2010-03-25
EP2207536A1 (en) 2010-07-21
BRPI0914192A2 (pt) 2015-11-03
US10751309B2 (en) 2020-08-25
MX2010004169A (es) 2010-10-05
US20160129116A1 (en) 2016-05-12
US20160128957A1 (en) 2016-05-12
WO2010034019A1 (en) 2010-03-25
US9566256B2 (en) 2017-02-14
CO6361907A2 (es) 2012-01-20
CA2702604C (en) 2013-12-03
WO2010034019A4 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
MX349176B (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
EA200901112A1 (ru) Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу
NZ701915A (en) High-concentration monoclonal antibody formulations
WO2010056922A3 (en) Systems and methods for delivery of biologically active agents
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
WO2011107755A3 (en) Immediate/delayed drug delivery
JP2017500374A5 (es)
WO2009029958A3 (en) Implantable delivery device
JP2016539921A5 (es)
IN2014DN09817A (es)
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
MX2009011900A (es) Curacion de herida diabetica.
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2008114376A1 (ja) メラニン生成抑制組成物
WO2012106058A3 (en) Animal treatments
IL273329A (en) Modulation of hepatic-hepatic epidermal growth factor activity to heal the eardrum membrane
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2012145554A3 (en) Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof
WO2015100348A8 (en) Keloid reduction using topical allantoin
WO2006091763A3 (en) Ultrasonically assisted dermal or transdermal delivery substance preparation
WO2012145555A3 (en) Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration